Dose-reduced conditioning before allogeneic stem cell transplantation: Principles, clinical protocols and preliminary results;Dosisreduzierte konditionierung vor allogener stammzelitransplantation: Grundprinzipien, klinische protokolle und erste ergebnisse

Deutsche Medizinische Wochenschrift

Volumn 127, Issue 42, 2002, Pages 2186-2192

  Schmid, Christoph ^a   Weisser, M ^a   Ledderose, G ^a   Stotzer O ^a   Schleuning, M ^a   Kolb, H J ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ANTINEOPLASTIC AGENT;

AGED; ALLOGRAFT; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HIGH RISK POPULATION; HUMAN; IMMUNE SYSTEM; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; MYELOID LEUKEMIA; PROGNOSIS; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; TREATMENT INDICATION; TREATMENT OUTCOME; WHOLE BODY RADIATION; ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; COMPARATIVE STUDY; DOSE RESPONSE; FEMALE; IMMUNOSUPPRESSIVE TREATMENT; MALE; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PHASE 2 CLINICAL TRIAL; RADIATION DOSE; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RADIOTHERAPY DOSAGE; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; WHOLE-BODY IRRADIATION;

EID: 0037130953     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-34946     Document Type: Article

References (36)

1. Anasetti C. Transplantation of hematopoietic stem cells from alternate donors in acute myelogenous leukemia. Leukemia 2000; 14: 502-504
2. Biggs JC, Horowitz MM, Gale RP et al. Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. Blood 1992; 80: 1090-1093
3. Bjorkstrand BB, Ljungman P, Svensson H et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: A retrospective case-matched study from the European group for blood and marrow transplantation. Blood 1996: 88: 4711-4718
4. Bornhauser M, Kiehl M, Siegert W et al. Dose-reduced conditioning for allografting in 44 patients with chronic myeloid leukaemia: A retrospective analysis. Br J Haematol 2001; 115: 119-124
5. Busca A, Anaseti C, Anderson F et al. Unrelated donor or autologous marrow transplantation for treatment of acute leukemia. Blood 1994; 83: 3077-3084
6. Clift R, Buckner C, Appelbaum C et al. Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia. J Clin Oncol 1992;10:1723-1729
7. Chakraverty R, Peggs K, Chopra R et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 2002; 99: 1071-1078
8. Champlin R. Chemotherapy based nonmyeloablative preparative regimens for allogeneic hematopietic transplantation. Hematology 2001. Washington DC: The American Society of Hematology, 2001: 379-383
9. Champlin R, Khouri 1, Shimoni A et al. Harnessing graft-versus-malignancy: Non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol 2000; 111: 18-29
10. Clift RA, Buckner CD, Thomas ED et al. Marrow transplantation for chronic myeloid leukemia: A randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 1994; 84: 2036-2043
11. Corradini P,Tarella C, Olivieri A et al. Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. Blood 2002; 99: 75-82
12. Ferrant A, Labopin M, Frassoni F et al. Karyotype in acute myeloblastic leukemia: Prognostic significance for bone marrow transplantation in first remission: A European Group for Blood and Marrow Transplantation Study. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Blood 1997; 90: 2931-2938
13. Forman SJ, Schmidt GM, Nademanee AP et al. Allogeneic bone marrow transplantation as therapy for primary induction failure for patients with acute leukemia. J Clin Oncol 1991; 9: 1570-1574
14. Giralt S, Thall PF, Khouri 1, Wang X et al. Melphalan and purine analog-containing preparative regimens: Reduced-intensity conditioning for patients with hematologic malignancies undergoing altogeneic progenitor cell transplantation. Blood 2001; 97: 631-637
15. Gratwohl A, Hermans J, Niederwieser D et al. Bone marrow transplantation for chronic myeloid leukemia: Long-term results. Chronic Leukemia Working Party of the European Group for Bone Marrow Transplantation. Bone Marrow Transplant 1993; 12: 509-516
16. Grever MR. Treatment of patients with acute nonlymphocytic leukemia not in remission. Semin Oncol 1987; 14: 416-424
17. Grimwade D, Walker H, Oliver F et al. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322-2333
18. Hegenbart U, Sandmeier B, Lange T et al. Related and unrelated allogeneic hematopoietic stem cell transplanta (HSCT) in patients with acute myeloid leukemia (AML) following minimla conditioning (Abstract). Bone Marrow Transplant 2002; IBMT Abstract Book: S56
19. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562
20. Kern W, Schoch C, Haferlach T et al. Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: Relevance of cytogenetic abnormalities. Leukemia 2000; 14: 226-231
21. Khouri IF, Keating M, Korbling M et al. Transplant-lite: Induction of graft-versus-malignancy using fludarabine- based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817-2824
22. Kolb H-J. Managment of relapse after hematopoietic cell transplantation. In Thomas, Blume, Forman (eds; 2nd ed) Hematopoietic Cell Transplantation. 1998; 2: 929-936
23. Kolb HJ, Mittermuller J, Clemm C et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462-2465
24. Lokhorst HM, Schattenberg A, Cornelissen JJ, Thomas LL, Verdonck LF. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 1997; 90: 4206-4211
25. Majolino I, Corradini P, Scime R et al. Allogeneic transplantation of unmanipulate peripheral blood stem cells in patients with multiple myeloma. Bone Marrow Transplant 1998; 22: 449-455
26. Martino R, Caballero MD, Canals C et al. Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: Results of a prospective multicentre study. Br J Haematol 2001; 115: 653-659
27. McSweeney PA, Niederwieser D, Shizuru JA et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390-3400
28. Mehta J, Tricot G, Jagannath S et al. Autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft? Bone Marrow Transplant 1998; 21: 887-892
29. Raanani P, Dazzi F, Sohal J et al. The Rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation. Br J Haematol 1997; 99: 945-950
30. Sawywers C, Hochhaus A, Feldmann E et al. Imatinib induces hematological and cytogenetic responses in patients witz chronic myelogenous leukemia in blast crisis: Results of a phase 11 trial. Blood 2002; 99: 3530-3539
31. Schmid C, Alessandrino E et al. Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with donor lymphocyte transfusion - A retrospective analysis aof EBMT results (Abstract). Blood 2000; 96 (Suppl 1); 477a
32. Storb R. Nonmyeloablative Preparative Regimens: How Relevant for Acute Myelogenous Leukemia? Leukemia 2001; 15: 662-663
33. Stötzer OJ, SchleuningM, Ledderose G, Hiddemann W, Kolb HJ. Allogene Transplantation maligner Lymphome (Abstract). Deut Med Wochenschr 2001; 126: 1062-1069
34. Sullivan KM, Storb R, Buckner CD et al. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N Engl J Med 1989; 320: 828-834
35. Talpaz M, Sawywers CL, Kantarjian H. Activity of an ABL specific tyrosine kinase inhibitor in patients with BCR-ABL positive acute leukemias including chronic myelogenous leukemia in blast crisis (Abstract). Proc ASCO 2000; 19: 4a
36. Weissinger F, Sandmaier BM, Maloney DG, Bensinger WI, Gooley T, Storb R. Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings. Blood 2001; 98: 3584-3588